Company intelligence / Profile preview

MiyaHealth

Ownership: Private
Development stage: Commercial

Overview

MiyaHealth has developed AI-driven SaaS platforms to improve healthcare efficiency across payors, providers, and patients. Its flagship product suites—MiyaPatient, MiyaPayor, and MiyaProvider—are deployed or piloted across Singapore, Indonesia, the Philippines, Poland/EU. The company’s GensuApp received ISO certification and a CE Mark as a Class I medical device in Europe for diabetes/chronic disease management. No clinical trial results are reported since these are digital health solutions rather than therapeutics.

Therapeutic areas: OtherEndocrinology
Modalities: Non-pharmacological therapy (digital health platform/software as a medical device)
Industry: Digital Health Medical Devices

Partnerships

Bioton S.A. (Poland) – co-development of GensuApp diabetes platform

Beyond the preview

Go deeper on MiyaHealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiyaHealth.

Explore the full profile